Enspryng (satralizumab) significantly reduced relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) in Phase III study.
List view / Grid view
Neuromyelitis optica spectrum disorder (NMOSD)
The Committee for Medicinal Products for Human Use (CHMP) recommended eight drugs for approval and nine indication extensions.
An injection to treat NMOSD has been given approval by the FDA and has received orphan drug designation.